Outpatient consumption of antibiotics with a bacterial resistance risk in 2014 in France

被引：2
作者：
Casaurancq, Marie-Celine [1 ,3 ]
de Campaigno, Emilie Patras [1 ,2 ]
Rueter, Manuela [1 ,2 ]
Baricault, Berangere [1 ,2 ]
Bourrel, Robert [4 ]
Lapeyre-Mestre, Maryse [1 ,2 ,3 ]
Sommet, Agnes [1 ,2 ,3 ]
机构：
[1] Univ Paul Sabatier, CHU Toulouse, Fac Med, Lab Pharmacol Med & Clin, F-31000 Toulouse, France
[2] INSERM, UMR1027, Equipe Pharmacoepidemiol Evaluat Utilisat & Risqu, F-31000 Toulouse, France
[3] CHU Toulouse, INSERM, CIC 1436, F-31000 Toulouse, France
[4] Midi Pyrenees, Direct Gen Serv Med Assurance Malad, F-31082 Toulouse, France
来源：
THERAPIE | 2017年 / 72卷 / 05期
关键词：
Antibacterial drug resistance; Ambulatory care; Consumption; Pharmaco-epidemiology; Geographic mapping;
D O I：
10.1016/j.therap.2017.03.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim. - This article proposes a description of French regional consumption of antibiotics with a bacterial resistance risk (amoxicillin+clavulanic acid, third-generation cephalosporins [C3G] and fluoroquinolones). Methods. - Antibiotics reimbursements data were obtained by Open Medic website. The antibiotic consumption profile has been established using some indicators of the European Surveillance of Antimicrobial Consumption (ESAC) in daily-defined dose per 1000 inhabitants per day (DID) or in percentage. Results. - Provence-Alpes-Cote d'Azur-Corse (34.4 DID) and Midi-Pyrenees-Languedoc-Roussillon (33.5 DID) consume the most of both, systemic antibiotics and antibiotics with a bacterial resistance risk. Pays-de-la-Loire (26.7 DID), Bretagne (29.1 DID), Centre-Val-de-Loire (29.7 DID) et Auvergne-Rhone-Alpes (29.7 DID) consume the less of both, systemic antibiotics and antibiotics with a bacterial resistance risk. Conclusion. - Even if some environmental and socioeconomic factors could explain variabilities between regions, a link between consumption intensity and misuse is not excluded. Copyright (C) 2017 Societe francaise de pharmacologie et de therapeutique. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：593 / 604
页数：12
相关论文
共 29 条
  • [1] [Anonymous], 2016, COLL CTR DRUG STAT M
  • [2] ANSM, 2011, DIX ANS EV CONS ANT
  • [3] ANSM, 2014, EV CONS ANT FRANC EN
  • [4] ANSM, 2016, LIST ANT CRIT ACT 20
  • [5] Azria R., 2012, Medecine et Maladies Infectieuses, V42, P460, DOI 10.1016/j.medmal.2012.02.004
  • [6] Bans N, 2009, NORMALISATION TAUX
  • [7] European Surveillance of antimicrobial consumption (ESAC): quality indicators for outpatient antibiotic use in Europe
    Coenen, Samuel
    Ferech, Matus
    Haaijer-Ruskamp, Flora M.
    Butler, Chris C.
    Stichele, Robert H. Vander
    Verheij, Theo J. M.
    Monnet, Dominique L.
    Goossens, Paul Little Herman
    [J]. QUALITY & SAFETY IN HEALTH CARE, 2007, 16 (06): : 440 - 445
  • [8] An antibiotic policy to prevent emergence of resistant bacilli
    de Man, P
    Verhoeven, BAN
    Verbrugh, HA
    Vos, MC
    van den Anker, JN
    [J]. LANCET, 2000, 355 (9208) : 973 - 978
  • [9] ESAC-Net, 2015, SUMM LAT DAT ANT CON
  • [10] Faculte de medecine, 2005, PAR ILE DE FRANC QUE
123